Aesthetic ProceduresNCT07261748
MENA Consensus on Poly-L-Lactic Acid (PLLA) Biostimulator Use in Aesthetic Dermatology
An observational study of Aesthetic Procedures and Cosmetic Techniques, run by Venus Research Center at 1 site in Egypt.
Trial summary
This study aims to develop expert consensus on the safe and effective use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. Read more about this study
- Who is it for?
- Ages 25 years and olderHealthy volunteers can take part
- Conditions the study is for
- Aesthetic Procedures, Cosmetic Techniques, Skin Aging
- How many people
- 15 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2025to Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: A purposively selected group of dermatology and aesthetic medicine experts from Egypt and the broader MENA region. Participants are clinicians with significant experience using poly-L-lactic acid (PLLA) biostimulators and are invited to contribute to a structured Modified Delphi process to develop regional consensus recommendations.
Who may be able to join
- Board-certified dermatologist or plastic surgeon OR physician practicing aesthetic medicine.
- Minimum of 5 years of clinical experience OR ≥50 documented PLLA cases.
- Practicing within Egypt or the Middle East and North Africa (MENA) region.
- Willingness to participate in Delphi rounds and provide expert ratings.
- Ability to read and respond to surveys in English.
Who cannot join
- Inability or unwillingness to complete Delphi rounds.
- Lack of clinical experience with PLLA.
- Industry representatives without direct clinical practice.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to develop expert consensus on the safe and effective use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is a commonly used injectable treatment that stimulates collagen production, but most guidelines come from Western populations and do not address the unique characteristics of Fitzpatrick III-VI skin types, which are predominant in the MENA region.
The study uses a Modified Delphi method, a well-established approach for collecting and refining expert agreement. Dermatologists and aesthetic physicians from MENA countries will participate in two to three online rounds of surveys. In Round 1, experts will answer open-ended questions about indications, contraindications, dilution techniques, safety concerns, anatomical considerations, and training needs related to PLLA. Their responses will be analyzed and converted into structured statements.
Read more
In Round 2, experts will rate each statement using a 1-to-9 Likert scale, indicating their level of agreement. Items with high agreement will form part of the final consensus. Statements with uncertain or conflicting ratings may undergo a third round for clarification.
No patients are involved in the study, and no treatments or interventions will be administered. The study collects professional opinions only, and all responses are anonymized during analysis. The final output will be a region-specific clinical guideline to support safer and more standardized PLLA use across the MENA region. Results will be published in peer-reviewed journals and shared with the aesthetic medical community.
Read the detailed description
Study Overview This study is a non-interventional, observational expert consensus project designed to develop region-specific guidelines for the use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is widely used for collagen stimulation and facial rejuvenation, but existing evidence and guidelines are derived primarily from Western populations. Given that Fitzpatrick III-VI skin types dominate the MENA region, and that anatomical, cultural, and safety considerations differ, a structured expert consensus is required to optimize clinical practice.
Study Design
This study uses a Modified Delphi methodology, incorporating principles from the RAND/UCLA Appropriateness Method. The Delphi process includes 2-3 survey rounds:
Round 1 (Qualitative Item Generation):
Experts complete an open-ended questionnaire addressing indications, contraindications, dilution protocols, injection techniques, safety concerns (including risk of papules and PIH), anatomical considerations, combination treatments, follow-up practices, regulatory issues, training requirements, and research priorities. Responses undergo thematic analysis to generate structured candidate statements.
Round 2 (Quantitative Consensus Rating):
The consolidated statements are rated using a 9-point Likert scale (1 = inappropriate, 9 = appropriate). Experts rate each item independently based on clinical relevance, safety, and applicability in MENA populations.
Optional Round 3:
Statements without clear consensus are redistributed with anonymized group statistics for re-rating. This step is used only if needed to refine borderline items.
Expert Panel Selection
Experts will be eligible if they meet at least two of the following:
- ≥5 years of aesthetic practice;
- ≥50 PLLA cases performed;
- Recognized trainer, lecturer, or KOL;
- Publications or academic contributions in aesthetic medicine;
- Active practice within Egypt or other MENA countries. Panel size will be 15-25 experts, ensuring geographic, academic, and experiential diversity.
Consensus Definitions
The study follows RAND/UCLA criteria:
- Consensus (Appropriate): Median 7-9 AND Disagreement Index (DI) < 1.0
- Consensus (Inappropriate): Median 1-3 AND DI < 1.0
- No Consensus: Median 4-6 OR DI ≥ 1.0
- Items with near-consensus may undergo a third Delphi round. Data Collection Tools
VRC-developed materials include:
- Full A-L Likert questionnaire
- Fillable PDF form
- Online REDCap/Google Forms instrument
- Round-2 survey booklet
- Excel master sheet for response tracking Statistical Analysis For each item, the following will be calculated: median, interquartile range, interpercentile range (IPR), IPR adjusted for symmetry (IPRAS), and the Disagreement Index. Items will be categorized by agreement level and summarized for publication. Subgroup analyses (e.g., GCC vs North Africa) may be performed.
Ethical Considerations This study does not involve patients, clinical interventions, or personal health information. Participation is voluntary. Expert responses are anonymized. No foreseeable risks are associated with participation, and the study qualifies as minimal-risk, non-interventional research.
Outcomes and Dissemination The primary outcome is a set of consensus-based, region-specific recommendations for PLLA use in aesthetic practice. Secondary outcomes include identification of training standards and research priorities. Results will be disseminated through peer-reviewed publications, conference presentations, and a VRC-branded clinical guideline.
- Conditions
- Aesthetic Procedures, Cosmetic Techniques, Skin Aging, Rejuvenation
- Keywords
- Poly-L-lactic acid, PLLA, Biostimulator, Aesthetic dermatology, Collagen biostimulation, MENA region, Delphi study, Expert consensus, Cosmetic injectables, Facial rejuvenation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Expert Panel | A cohort of dermatology and aesthetic medicine experts from the MENA region participating in a Modified Delphi process to develop consensus recommendations on PLLA biostimulator use. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Achievement of Consensus on PLLA Clinical Practice Statements
The primary outcome is the proportion of Delphi statements reaching consensus among expert panelists. Consensus is defined using RAND/UCLA criteria: a median rating of 7-9 on a 9-point Likert scale with a Disagreement Index (DI) < 1.0. Statements will be categorized as "consensus appropriate," "consensus inappropriate," or "no consensus."
Measured: 6-12 weeks
Secondary outcomes (1)
Expert Rating Distribution Across PLLA Practice Domains
Distribution of Likert scores (1-9) for each PLLA practice statement across domains (patient selection, dilution, technique, safety, anatomy, consent, combinations, ultrasound use, follow-up, regulatory, training, research priorities). Medians, interquartile ranges, and DI will be calculated.
Measured: 6-12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2025
- Study start1 Nov 2025
- Primary completionJul 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aesthetic ProceduresStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Venus Research Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07261748
- Sponsor's protocol ID
- PLLA-VenusRC
- Status last verified
- Nov 2025
- First submitted
- 22 Nov 2025
- Last updated
- 3 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Delphi studies do not collect patient data, medical records, biological samples, or identifiable clinical information. Experts only give opinions, not "IPD." Their responses are anonymized, and sharing identifiable expert-level responses is not required and often discouraged
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MENA Consensus on Poly-L-Lactic Acid (PLLA) Biostimulator Use in Aesthetic Dermatology
- ClinicalTrials.gov ID
- NCT07261748
- Acronym / sponsor ID
- PLLA-VenusRC
- Conditions
- Aesthetic Procedures, Cosmetic Techniques, Skin Aging, Rejuvenation
- Keywords
- Poly-L-lactic acid, PLLA, Biostimulator, Aesthetic dermatology, Collagen biostimulation, MENA region, Delphi study, Expert consensus
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- Venus Research CenterUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 3 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to develop expert consensus on the safe and effective use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is a commonly used injectable treatment that stimulates collagen production, but most guidelines come from Western populations and do not address the unique characteristics of Fitzpatrick III-VI skin types, which are predominant in the MENA region.
The study uses a Modified Delphi method, a well-established approach for collecting and refining expert agreement. Dermatologists and aesthetic physicians from MENA countries will participate in two to three online rounds of surveys. In Round 1, experts will answer open-ended questions about indications, contraindications, dilution techniques, safety concerns, anatomical considerations, and training needs related to PLLA. Their responses will be analyzed and converted into structured statements.
In Round 2, experts will rate each statement using a 1-to-9 Likert scale, indicating their level of agreement. Items with high agreement will form part of the final consensus. Statements with uncertain or conflicting ratings may undergo a third round for clarification.
No patients are involved in the study, and no treatments or interventions will be administered. The study collects professional opinions only, and all responses are anonymized during analysis. The final output will be a region-specific clinical guideline to support safer and more standardized PLLA use across the MENA region. Results will be published in peer-reviewed journals and shared with the aesthetic medical community.
Detailed description
Study Overview This study is a non-interventional, observational expert consensus project designed to develop region-specific guidelines for the use of poly-L-lactic acid (PLLA) biostimulators in aesthetic dermatology across the Middle East and North Africa (MENA) region. PLLA is widely used for collagen stimulation and facial rejuvenation, but existing evidence and guidelines are derived primarily from Western populations. Given that Fitzpatrick III-VI skin types dominate the MENA region, and that anatomical, cultural, and safety considerations differ, a structured expert consensus is required to optimize clinical practice.
Study Design
This study uses a Modified Delphi methodology, incorporating principles from the RAND/UCLA Appropriateness Method. The Delphi process includes 2-3 survey rounds:
Round 1 (Qualitative Item Generation):
Experts complete an open-ended questionnaire addressing indications, contraindications, dilution protocols, injection techniques, safety concerns (including risk of papules and PIH), anatomical considerations, combination treatments, follow-up practices, regulatory issues, training requirements, and research priorities. Responses undergo thematic analysis to generate structured candidate statements.
Round 2 (Quantitative Consensus Rating):
The consolidated statements are rated using a 9-point Likert scale (1 = inappropriate, 9 = appropriate). Experts rate each item independently based on clinical relevance, safety, and applicability in MENA populations.
Optional Round 3:
Statements without clear consensus are redistributed with anonymized group statistics for re-rating. This step is used only if needed to refine borderline items.
Expert Panel Selection
Experts will be eligible if they meet at least two of the following:
- ≥5 years of aesthetic practice;
- ≥50 PLLA cases performed;
- Recognized trainer, lecturer, or KOL;
- Publications or academic contributions in aesthetic medicine;
- Active practice within Egypt or other MENA countries. Panel size will be 15-25 experts, ensuring geographic, academic, and experiential diversity.
Consensus Definitions
The study follows RAND/UCLA criteria:
- Consensus (Appropriate): Median 7-9 AND Disagreement Index (DI) < 1.0
- Consensus (Inappropriate): Median 1-3 AND DI < 1.0
- No Consensus: Median 4-6 OR DI ≥ 1.0
- Items with near-consensus may undergo a third Delphi round. Data Collection Tools
VRC-developed materials include:
- Full A-L Likert questionnaire
- Fillable PDF form
- Online REDCap/Google Forms instrument
- Round-2 survey booklet
- Excel master sheet for response tracking Statistical Analysis For each item, the following will be calculated: median, interquartile range, interpercentile range (IPR), IPR adjusted for symmetry (IPRAS), and the Disagreement Index. Items will be categorized by agreement level and summarized for publication. Subgroup analyses (e.g., GCC vs North Africa) may be performed.
Ethical Considerations This study does not involve patients, clinical interventions, or personal health information. Participation is voluntary. Expert responses are anonymized. No foreseeable risks are associated with participation, and the study qualifies as minimal-risk, non-interventional research.
Outcomes and Dissemination The primary outcome is a set of consensus-based, region-specific recommendations for PLLA use in aesthetic practice. Secondary outcomes include identification of training standards and research priorities. Results will be disseminated through peer-reviewed publications, conference presentations, and a VRC-branded clinical guideline.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Expert Panel | – | –A cohort of dermatology and aesthetic medicine experts from the MENA region participating in a Modified Delphi process to develop consensus recommendations on PLLA biostimulator use. |
Who may qualify
- Ages
- 25 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- A purposively selected group of dermatology and aesthetic medicine experts from Egypt and the broader MENA region. Participants are clinicians with significant experience using poly-L-lactic acid (PLLA) biostimulators and are invited to contribute to a structured Modified Delphi process to develop regional consensus recommendations.
Key inclusion criteria (5 listed)
- Board-certified dermatologist or plastic surgeon OR physician practicing aesthetic medicine.
- Minimum of 5 years of clinical experience OR ≥50 documented PLLA cases.
- Practicing within Egypt or the Middle East and North Africa (MENA) region.
- Willingness to participate in Delphi rounds and provide expert ratings.
- Ability to read and respond to surveys in English.
Key exclusion criteria (3 listed)
- Inability or unwillingness to complete Delphi rounds.
- Lack of clinical experience with PLLA.
- Industry representatives without direct clinical practice.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Achievement of Consensus on PLLA Clinical Practice Statements
Time frame: 6-12 weeks
The primary outcome is the proportion of Delphi statements reaching consensus among expert panelists. Consensus is defined using RAND/UCLA criteria: a median rating of 7-9 on a 9-point Likert scale with a Disagreement Index (DI) < 1.0. Statements will be categorized as "consensus appropriate," "consensus inappropriate," or "no consensus."
1 secondary outcome
Expert Rating Distribution Across PLLA Practice Domains
Time frame: 6-12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2025.
- Individual participant dataSharing planned: No. Delphi studies do not collect patient data, medical records, biological samples, or identifiable clinical information. Experts only give opinions, not "IPD." Their responses are anonymized, and sharing identifiable expert-level responses is not required and often discouraged
Related trials for Aesthetic Procedures
RecruitingObservational study
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
Post Procedural Erythema
Active, not recruiting
Clinical Performance and Safety of STYLAGE® HydroMax
Aging, Aesthetic
Active, not recruiting
Enhancing Soft Tissues Around Inserted Implants by Two Different Methods
Missing Teeth
Not yet recruiting
Predictable Method for Restoring Endodontically Treated Teeth, Comparing Indirect and Direct Methods and Materials in Aesthetic Dentistry.
Endodontically Treated Teeth Requiring Indirect Restorative Treatment
Active, not recruiting
Hybrid Osteoplasty Versus Osteotomy in Rhinoplasty
Rhinoplasty Techniques
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aesthetic Procedures and Cosmetic Techniques, run by Venus Research Center at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Achievement of Consensus on PLLA Clinical Practice Statements (time frame: 6-12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.